Newsweek Learning English: teksty po angielsku w Newsweeku

For those now grappling with Alzheimer’s, lecanemab holds out the promise of slowing the disease’s progress. Are the modest benefits worth the risks? (C1)

Related Keywords

,Babak Tousi ,Jason Karlawish ,Ralph Nixon ,Madhav Thambisetty ,Grossman School Of Medicine ,National Institute On ,Drug Administration ,Penn Memory Center ,New England Journal ,National Institute ,Risk Evaluation ,Mitigation Strategy ,Cleveland Clinic ,Cell Biology ,Nature Neuroscience ,Newsweek Learning English ,